Cancer’s become a core area of venture capital interest, particularly given the rise of personalized medicine. But in a cluttered marketplace it’s tough to differentiate the worthy from the chaff. Here are some observations from a panel of investors said at the Cleveland Clinic Medical Innovation Summit Monday:

- “Pharma’s really very good at distributing medicines, but not that good at innovating and developing them anymore,” Ashley Dombkowski, a managing director at Bay City Capital said.

Image: http://medcitynews.com